Major diseases manifesting by vestibular vertigo: Treatment and rehabilitation

Betahistine hydrochloride is the drug of choice for the treatment of vestibular vertigo in the presence of benign paroxysmal positional vertigo, Meniere's disease, and vestibular neuronitis. Effective combination therapy regimens that contain, along with drugs from other pharmacological groups, betahistine hydrochloride that improves blood circulation in the vestibular structures, accelerates vestibular compensation, and prevents recurrent dizzy spells, have been elaborated to treat central vestibular vertigo in migraine-associated dizziness and in acute cerebrovascular accident. Of great importance is a combination of drug therapy and the current rehabilitation methods for vestibular diseases, which contribute to prompter and complete recovery of vestibular function. Biofeedback instrumental rehabilitation techniques using a stabilographic platform
are highly effective. Successful treatment depends on the correctness of the established diagnosis. The diagnosis of peripheral and central vestibular vertigo frequently poses challenges. The essential reason for this is physicians’ unawareness about outpatient methods for the diagnosis of major vestibular diseases when the patient is at a doctor. It is important to follow a vestibular system study protocol since the use and correct assessment of diagnostic tests in most cases make it possible to estimate the degree of vestibular analyzer injury and to make an accurate diagnosis. The paper describes the diseases that are the most common causes of vestibular vertigo. The most effective methods for their treatment and current rehabilitation methods are discussed.

1. Морозова СВ, Зайцева ОВ, Налетова НА. Головокружение как медико-социальная проблема. Русский Медицинский Журнал. 2002;(4):164. [Morozova SV, Zaitseva OV, Naletova NA. Dizziness as a health and social problem. Russkii Meditsinskii Zhurnal. 2002;(4):164 (In Russ.)].

2. Colledge NR, Barr-Hamilton RM. Evaluation of investigations to diagnose the cause of dizziness in elderly people: a community based controlled study. BMJ. 1996 Sep 28;313(7060):788–92.

3. Neuhauser HK, von Brevern M, Radtke A, et al. Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology. 2005 Sep 27;65(6):898–904.

4. Парфенов ВА, Замерград МВ, Мельников ОА. Головокружение диагностика, лечение, распространенные диагностические ошибки. Учебное пособие. Москва: Медицинское информационное агентство; 2011. 190 с. [Parfenov VA, Zamergrad MV, Mel'nikov OA. Golovokruzhenie diagnostika, lechenie, rasprostranennye diagnosticheskie oshibki [Dizziness: diagnosis, treatment, common diagnostic errors]. Moscow: Meditsinskoe informatsionnoe agentstvo; 2011. 190 p.]

5. Brandt Т, Dieterich М. Vertigo and dizziness: common complains. London: Springer; 2004. 208 p.

6. Brandt T. Vertigo. Its Multisensory Syndromes. London: Springer; 2000. 504 p.

7. Redon C, Lopez C, Bernard-Demanze L, et al. Betahistine treatment improves the ecovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol. 2011 Apr;51(4):538–48. doi: 10.1177/00912700 10369241. Epub 2010 Oct 12.

8. Strupp M, Thurtell MJ, Shaikh AG, et al. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol. 2011 Jul;258(7):1207–22. doi: 10.1007/s00415- 011-5999-8. Epub 2011 Apr 2.

9. Kanashiro AMK, Pereira CB, Melo AC, et al. Diagnosis and treatment of the most frequent vestibular syndromes. Arq Neuropsiquiatr. 2005 Mar;63(1):140–4. Epub 2005 Apr 13.

10. Антоненко ЛМ, Бестужева НВ, Парфенов ВА. Применение препаратов бетагистина при головокружении. Медицинский совет. 2014;(18):34–40. [Antonenko LM, Bestuzheva NV, Parfenov VA. The use of betahistine in dizziness. Meditsinskii sovet. 2014;(18):34–40. (In Russ.)].

11. Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo. Elucidation of mechanisms of action. CNS Drugs. 2001;15(11):853–70.

12. Lezius F, Adrion C, Mansmann U, et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniеre's disease: a case series. Eur Arch Otorhinolaryngol. 2011 Aug;268(8):1237–40. doi: 10.1007/s00405-011-1647-2. Epub 2011 May 29.

13. Meyer P, Schmidt R, Grutzmacher W, et al. Inner ear blood flow with betahistine – an animal experiment study. Laryngorhinootologie. 1994 Mar;73(3):153–6.

14. Tighilet B, Leonard J, Lacour M. Betahistine dihydrochloride treatment facilitates vestibular compensation in the cat. J Vestib Res. 1995 Jan-Feb;5(1):53–66.

15. Benecke H, Herminio Perez-Garrigues MD, Dinsuhaimi bin Sidek MD, et al. Effects of Betahistine on Patient-Reported Outcomes in Routine Practice in Patients with Vestibular Vertigo and Appraisal of Tolerability: Experience in the OSVaLD Study. Int Tinnitus J. 2010;16(1):14–24.

16. Mira E, Guidetti G, Ghilardi L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol. 2003 Feb;260(2):73–7. Epub 2002 Sep 11.

17. Замерград МВ, Антоненко ЛМ. Посттравматическое головокружение. Неврологический журнал. 2012;(2):4-10. [Zamergrad MV, Antonenko LM. Posttraumatic vertigo. Nevrologicheskii zhurnal. 2012;(2):4–10. (In Russ.)].

18. Brandt Т, Huppert I, Hecht J, et al. Benign paroxysmal positioning vertigo: a long-term followup (6–17 years) of 125 patients. Acta Otolaryngol. 2006 Feb;126(2):160–3.

19. Fife TD. Benign paroxysmal positional vertigo. Semin Neurol. 2009 Nov;29(5):500–8. doi: 10.1055/s-0029-1241041. Epub 2009 Oct 15.

20. Gates GA. Meniere's disease review 2005. J Am Acad Audiol. 2006 Jan;17(1):16–26.

21. Strupp M, Hupert D, Frenzel С, et al. Long-term prophylactic treatment of attacks of vertigo in Meniere’s disease comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol. 2008 May;128(5):520–4. doi: 10.1080/00016480701724912.

22. Morris AE, Lutman ME, Yardley L. Measuring outcome from vestibular rehabilitation, part II: refinement and validation of a new self-report measure. Int J Audiol. 2009 Jan;48(1):24-37. doi: 10.1080/14992020802314905.

23. Dieterich M, Brandt T. Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol. 1999 Oct;246(10):883–92.

24. Crevits L, Bosman T. Migraine-related vertigo towards a distinctive entity. Clin Neurol Neurosurg. 2005 Feb;107(2):82–7.

25. Парфенов ВА, Абдулина ОВ, Замерград МВ. Периферическая вестибулопатия под маской инсульта. Неврологический журнал. 2005;(6):28–32. [Parfenov VA, Abdulina OV, Zamergrad MV. Peripheral vestibulopathy under the mask of a stroke. Nevrologicheskii zhurnal. 2005;(6):28–32. (In Russ.).]

26. Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.]

27. Geser R, Straumann D. Referral and final diagnoses of patients assessed in an academic vertigo center. Front Neurol. 2012 Nov 28;3:169. doi: 10.3389/fneur.2012. 00169. eCollection 2012.

28. Pollak L. Awareness of benign paroxysmal positional vertigo in central Israel. BMC Neurol. 2009 Apr 22;9:17. doi: 10.1186/1471-2377-9-17.